Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2026-04-30 Annual Report
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox annonce ses résultats financiers 2025 et fait un point sur son activité
Annual Report Classification · 95% confidence The document is a detailed financial announcement titled "Nicox annonce ses résultats financiers 2025 et fait un point sur son activité" which translates to "Nicox announces its 2025 financial results and provides an update on its activity." It includes comprehensive financial data such as income statement, balance sheet, and detailed commentary on revenues, losses, and strategic outlook. The document references the fiscal year 2025 and contains actual financial statements and analysis. It is not a brief announcement or a notice of report publication but a full financial report for the year. Therefore, it fits the definition of an Annual Report (10-K equivalent).
2026-04-30 French
Nicox Provides Full Year 2025 Financial Results and Corporate Update
Annual Report Classification · 95% confidence The document is a press release dated April 30, 2026, providing full year 2025 financial results and a corporate update for Nicox SA. It includes detailed financial data such as revenue, net loss, operating expenses, income statement, and balance sheet figures for the full fiscal year 2025. The document also discusses future milestones, regulatory updates, and strategic plans. The presence of comprehensive financial statements and analysis for the full fiscal year indicates this is a full annual financial report rather than a brief earnings release or announcement. The document length (11,641 characters) and detailed financial tables confirm it is not a short announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K) type filing, as it covers the company's full year financial performance and activities.
2026-04-30 English
Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026
Share Issue/Capital Change Classification · 85% confidence The document is a press release reminding warrant holders (BSA) of the final exercise date and outlining the terms (ISIN, exercise period, parity, price) and potential share issuance (4,009,038 new shares). It is not a full financial report or earnings release but an announcement about a capital change (exercise of warrants leading to share issuance). This matches our category for share issue/capital change announcements (SHA).
2026-04-20 French
Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
Capital/Financing Update Classification · 85% confidence The document is a press release reminding warrant holders of the expiration and exercise terms of the company’s June 2024 equity warrants. It deals with the company’s capital structure and financing instrument (warrants), rather than financial results, management changes, or dividend information. Therefore it is best classified as a Capital/Financing Update (CAP).
2026-04-20 English
Nicox présente des données de Phase 3 positives confirmant le profil thérapeutique de NCX 470 lors du congrès annuel 2026 de l’American Glaucoma Society (AGS)
Investor Presentation Classification · 90% confidence The document is a press release from Nicox SA announcing positive Phase 3 clinical trial data for their drug NCX 470 presented at the 2026 American Glaucoma Society annual congress. It details clinical trial results, presentations, and posters at a scientific conference. There is no financial data, regulatory filing, or report attached or referenced as being published. The content is focused on clinical trial results and scientific presentations rather than financial or corporate governance information. This type of document is best classified as an Investor Presentation (IP) because it provides detailed information aimed at investors about the company's clinical progress and potential market impact of their drug. It is not an Annual Report, Earnings Release, or Regulatory Filing. The length and detail support a confidence score of 0.9.
2026-02-24 French
Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
Regulatory Filings Classification · 95% confidence The document is a press release issued by Nicox SA announcing positive clinical trial results (Phase 3 data for NCX 470) presented at a scientific conference (American Glaucoma Society). It does not fit into financial reporting categories like 10-K or IR, nor is it a regulatory filing or a report publication announcement. As it is a general corporate announcement regarding business/scientific progress that does not fall into the other specific categories, it is classified as a Regulatory Filing (RNS).
2026-02-24 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.